Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland.
Clinical Research Centre (CRC) & Division of Clinical Epidemiology, Department of Health and Community Medicine, University of Geneva and Geneva University Hospitals, Geneva, Switzerland.
Front Immunol. 2022 Feb 10;12:820126. doi: 10.3389/fimmu.2021.820126. eCollection 2021.
This study aims to assess the immunological response and impact on virological control of the mRNA vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among people living with HIV (PLWH). In this single-center observational study, all PLWH were offered vaccination with mRNA1273 or BNT162b2. Both anti-N and anti-S1-receptor binding domain (RBD) antibodies were measured together with HIV-1 RNA levels after the first dose (M0) and then at 1 (M1), 2 (M2) and 6 (M6) months later. A total of 131 individuals (median age: 54 years [IQR: 47.0-60.5]; male: 70.2%; median baseline CD4 T-cell: 602/µl [IQR 445.0-825.5]; median nadir CD4 T-cells 223/µl [IQR 111.0-330.0]) were included. All participants were positive for anti-RBD antibodies at 30 days, 60 days and 6 months after the first dose, with no statistical difference between those with HIV-1 RNA below or >20 copies/ml. HIV-1 RNA data were collected for 128 patients at baseline and 30 days after the first dose; for 124 individuals, 30 days after the second dose; and for 83 patients, 6 months after the first dose. Nineteen (14.8%) of 128 had detectable HIV-1 RNA (>20 copies/ml) at M0, 13/128 (10.2%) at M1 (among which 5 were newly detectable), 15/124 (12.1%) at M2 (among which 5 were newly detectable), and 8/83 (9.6%) at M6. No serious adverse effects were reported. All participants elicited antibodies after two doses of mRNA vaccines, with only a minor impact on HIV-1 RNA levels over a 6-month period.
本研究旨在评估针对严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 的 mRNA 疫苗在艾滋病毒感染者 (PLWH) 中的免疫反应和对病毒学控制的影响。在这项单中心观察性研究中，所有 PLWH 均接种了 mRNA1273 或 BNT162b2 疫苗。在第一剂（M0）后以及 1 个月（M1）、2 个月（M2）和 6 个月（M6）后，同时测量了抗 N 和抗 S1 受体结合域 (RBD) 抗体以及 HIV-1 RNA 水平。共纳入 131 名个体（中位年龄：54 岁[IQR：47.0-60.5]；男性：70.2%；中位基线 CD4 T 细胞：602/µl [IQR 445.0-825.5]；中位最低 CD4 T 细胞：223/µl [IQR 111.0-330.0]）。所有参与者在第一剂后 30 天、60 天和 6 个月时均对 RBD 抗体呈阳性，HIV-1 RNA 低于或 >20 拷贝/ml 的患者之间无统计学差异。在基线和第一剂后 30 天收集了 128 名患者的 HIV-1 RNA 数据；在第二剂后 30 天收集了 124 名患者的数据；在第一剂后 6 个月收集了 83 名患者的数据。在 M0 时，128 名患者中有 19 名（14.8%）可检测到 HIV-1 RNA（>20 拷贝/ml），128 名患者中有 13 名（10.2%）在 M1 时（其中 5 名新检测到），124 名患者中有 15 名（12.1%）在 M2 时（其中 5 名新检测到），83 名患者中有 8 名（9.6%）在 M6 时。未报告严重不良事件。所有参与者在接种两剂 mRNA 疫苗后均产生了抗体，在 6 个月内仅对 HIV-1 RNA 水平产生轻微影响。
Zotero 插件
